Temozolomide A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers

[1]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[2]  E. Raymond,et al.  Activity of temozolomide against human tumor colony-forming units. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  D. Osoba,et al.  Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. , 2000, European journal of cancer.

[4]  S. Nutik,et al.  Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. , 1985, Journal of neurosurgery.

[5]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[6]  N. Bleehen,et al.  A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. , 1989, International journal of radiation oncology, biology, physics.

[7]  B. Durkacz,et al.  (ADP-ribose)n participates in DNA excision repair , 1980, Nature.

[8]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[9]  T. Mok,et al.  Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma , 1998, Cancer Chemotherapy and Pharmacology.

[10]  C. G. Newton,et al.  Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. , 1984, Journal of medicinal chemistry.

[11]  R. McLendon,et al.  Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Tentori,et al.  Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. , 1995, Leukemia.

[14]  P. Beale,et al.  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.

[15]  M. Dolan,et al.  O6-benzylguanine and its role in chemotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  S. Keir,et al.  Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. , 1997, Cancer research.

[17]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[18]  J. Jiricny,et al.  Involvement of the mismatch repair system in temozolomide-induced apoptosis. , 1998, Molecular pharmacology.

[19]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Prados.  Temozolomide in combination with other cytotoxic agents. , 2001, Seminars in oncology.

[21]  G. Margison,et al.  O6‐(4‐bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts , 2000, International journal of cancer.

[22]  D. Osoba,et al.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires , 1996, Quality of Life Research.

[23]  E. Bröcker,et al.  Classical chemotherapy for metastatic melanoma , 2000, Clinical and experimental dermatology.

[24]  O. S. Nielsen,et al.  Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. , 1999, European journal of cancer.

[25]  J. Heimans,et al.  Survival of human glioma cells treated with various combination of temozolomide and X-rays. , 2000, International journal of radiation oncology, biology, physics.

[26]  J. Buckner,et al.  Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  D. Osoba.  What has been learned from measuring health-related quality of life in clinical oncology. , 1999, European journal of cancer.

[28]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[29]  M. Dolan,et al.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Grochow,et al.  Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  H Evans,et al.  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas , 2000, British Journal of Cancer.

[32]  N. Curtin,et al.  Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. , 1995, British Journal of Cancer.

[33]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[34]  G. Reaman,et al.  Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  W. Yung.  Future directions for temozolomide therapy. , 2001, Seminars in oncology.

[36]  A. Arance,et al.  O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study , 2000, International journal of cancer.

[37]  M. Stevens,et al.  NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.

[38]  M. Dolan,et al.  Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.

[39]  M. Busstra,et al.  A phase II study of temozolomide in hormone-refractory prostate cancer , 2000, Cancer Chemotherapy and Pharmacology.

[40]  E. Newlands,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[41]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[43]  L. Tentori,et al.  Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. , 1997, Molecular pharmacology.

[44]  E S Newlands,et al.  Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.

[45]  M. Tisdale.  Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. , 1987, Biochemical pharmacology.

[46]  E. Newlands,et al.  O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. , 1996, British Journal of Cancer.

[47]  M. Berger,et al.  Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. , 2001, Cancer research.

[48]  P. Lacal,et al.  O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity. , 1999, The Journal of pharmacology and experimental therapeutics.

[49]  J. Wyngaarden,et al.  Utilization of hypoxanthine, adenine and 4-amino-5-imidazole-carboxamide for uric acid synthesis in man. , 1959, Metabolism: clinical and experimental.

[50]  P. Beale,et al.  Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide , 1999, Cancer Chemotherapy and Pharmacology.

[51]  S. Gerson,et al.  Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  P. Houghton,et al.  Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  D. Crowther,et al.  Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. , 1995, British Journal of Cancer.

[54]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Prados,et al.  A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. , 2000, Neuro-oncology.

[56]  E. Newlands,et al.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. , 1996, British Journal of Cancer.

[57]  P. Kosmidis,et al.  Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  W. Robinson,et al.  Melanoma: epidemiology, pathogenesis, and new modes of treatment. , 1996, Advances in internal medicine.

[59]  D. V. Von Hoff,et al.  A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  R. McLendon,et al.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  N. Bleehen,et al.  Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma , 1997, Cancer Chemotherapy and Pharmacology.

[62]  E. Newlands,et al.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. , 1996, British Journal of Cancer.

[63]  A. Oza,et al.  A phase II study of Temozolomide in advanced untreated pancreatic cancer , 2004, Investigational New Drugs.

[64]  S. Markowitz,et al.  Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. , 1996, Cancer research.

[65]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  M. Prados.  Future directions in the treatment of malignant gliomas with temozolomide. , 2000, Seminars in oncology.

[67]  A. Brandes,et al.  Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. , 2001, Annals of Oncology.

[68]  E. Newlands,et al.  The Charing Cross Hospital experience with temozolomide in patients with gliomas. , 1996, European journal of cancer.

[69]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[70]  J M BUCHANAN,et al.  Biosynthesis of the purines. XVI. The synthesis of adenosine 5'-phosphate and 5-amino-4-imidazolecarboxamide ribotide by a nucleotide pyrophosphorylase. , 1957, The Journal of biological chemistry.

[71]  Sudhakar M. Pai,et al.  Population Pharmacokinetics of Temozolomide in Cancer Patients , 2000, Pharmaceutical Research.

[72]  M. Stevens,et al.  Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC. , 1992, Journal of medicinal chemistry.

[73]  A. Friedman,et al.  Chemotherapy for adults with malignant glioma. , 1999, Cancer investigation.

[74]  H. Gogas,et al.  Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. Stevens,et al.  Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. , 1998, British Journal of Cancer.

[76]  T. Buclin,et al.  Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration , 1998, Cancer Chemotherapy and Pharmacology.

[77]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  R. Stupp,et al.  New approaches for temozolomide therapy: use in newly diagnosed glioma. , 2001, Seminars in oncology.

[79]  D. Osoba,et al.  Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer , 1997, Quality of Life Research.

[80]  D. Osoba,et al.  Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  W. Hwu.  New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. , 2000, Oncology.

[82]  J. Thigpen,et al.  A Preliminary Study of CA15-3, c-erbB-2, Epidermal Growth Factor Receptor, Cathepsin-D, and p53 in Saliva Among Women with Breast Carcinoma , 2000, Cancer investigation.

[83]  D. Thomas,et al.  Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. , 1999, Anti-cancer drugs.

[84]  W. R. Bishop,et al.  Treatment of neoplastic meningitis with intrathecal temozolomide. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  A. Pegg,et al.  Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.

[86]  T. Batchelor,et al.  New treatment strategies for malignant gliomas. , 1999, The oncologist.

[87]  A. Monks,et al.  Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen , 2000, Cancer Chemotherapy and Pharmacology.

[88]  C. Whitacre,et al.  Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  J. Reid,et al.  Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[91]  M R Grever,et al.  Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1994, Cancer research.

[92]  E. Newlands,et al.  Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.

[93]  R. Kolodner,et al.  Biochemistry and genetics of eukaryotic mismatch repair. , 1996, Genes & development.

[94]  I. Faraoni,et al.  O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. , 1995, Cancer research.

[95]  M. Stevens,et al.  Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. , 1995, Journal of medicinal chemistry.

[96]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[97]  H. Friedman,et al.  Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.